Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects.
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects.
复制标题
用于实体瘤的嵌合抗原受体修饰 T 细胞：挑战与前景
DOI：
10.1155/2016/3850839
复制
发表时间：
2016
影响因子：
4.1
通讯作者：
Han W
中科院分区：
文献类型：
--
作者：
Guo Y;Wang Y;Han W
最近的研究强调了基于嵌合抗原受体修饰的 T 细胞 (CART-) 治疗 B 细胞恶性肿瘤的成功，并且近年来已启动早期临床试验。为数不多的已发表的 CART 细胞治疗实体瘤的临床研究已经解决了安全性和可行性，但临床结果数据有限。尽管抗肿瘤作用在体外和动物模型中得到证实，但基于CART细胞的疗法在针对实体瘤时仍面临一些挑战，在临床实践中很难达到预期的效果。许多研究一直在努力提高 CART 细胞治疗实体瘤的临床反应和益处。本综述首先对CART细胞的现状及其在实体瘤的临床应用进行综述。重要的是，我们将提出改进建议，以提高 CART 细胞对实体瘤的治疗效果及其未来的临床应用。这些干预措施将使 CART 细胞治疗成为实体瘤的有效常规疗法。
Recent studies have highlighted the successes of chimeric antigen receptor-modified T- (CART-) cell-based therapy for B-cell malignancies, and early phase clinical trials have been launched in recent years. The few published clinical studies of CART cells in solid tumors have addressed safety and feasibility, but the clinical outcome data are limited. Although antitumor effects were confirmed in vitro and in animal models, CART-cell-based therapy still faces several challenges when directed towards solid tumors, and it has been difficult to achieve the desired outcomes in clinical practice. Many studies have struggled to improve the clinical responses to and benefits of CART-cell treatment of solid tumors. In this review, the status quo of CART cells and their clinical applications for solid tumors will be summarized first. Importantly, we will suggest improvements that could increase the therapeutic effectiveness of CART cells for solid tumors and their future clinical applications. These interventions will make treatment with CART cells an effective and routine therapy for solid tumors.